https://www.selleckchem.com/products/cm-4620.html
This study aimed to determine the relative effectiveness and safety of secukinumab, ixekizumab, and tofacitinib in patients with psoriatic arthritis (PsA) showing insufficient responses to tumor necrosis factor (TNF) inhibitors. A Bayesian network meta-analysis was conducted using direct and indirect data from five randomized controlled trials that examined the efficacy and safety of secukinumab 150 mg or 300 mg every 4 weeks, subcutaneously injected ixekizumab 80 mg every 2 weeks (Q2W) or every 4 weeks (Q4W), and tofacitinib 5 mg or 10
Me gusta
Comentario
Compartir
